Journal of Antimicrobial Chemotherapy (2001) 47, 789-799
© 2001 The British Society for Antimicrobial Chemotherapy
Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test
Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale Avenue, London NW9 5HT, UK
A survey was conducted in 1999, first to establish the prevalence of antibiotic resistance among clinical isolates of Pseudomonas aeruginosa in the UK and secondly to test whether the use of the standardized British Society for Antimicrobial Chemotherapy (BSAC) disc testing method improved the accuracy of routine susceptibility testing for this organism. Twenty-five hospitals were each asked to collect up to 100 consecutive, clinically significant isolates of P. aeruginosa and to test their susceptibility to amikacin, gentamicin, ceftazidime, imipenem, meropenem, ciprofloxacin, piperacillin and piperacillin/tazobactam using the new BSAC disc method. A total of 2194 isolate reports were available for analysis and 10% of the isolates represented, plus those with unusual resistances, were re-tested centrally for quality control purposes. The zone distributions were essentially unimodal, indicating the absence of major populations with acquired resistance. The results indicated that resistance rates to the ß-lactam, aminoglycoside and quinolone agents tested in P. aeruginosa in the UK remain low (<12%), and were mostly unchanged since a previous survey conducted in 1993. High resistance rates were nevertheless reported for isolates from cystic fibrosis patients. The accuracy of susceptibility testing using the new BSAC disc testing method was better than in previous studies, when Stokes' method was most frequently used. Critically, the proportion of resistant isolates incorrectly reported as susceptible was reduced significantly; nevertheless, depending on the antibiotic, up to 49% of the isolates reported as intermediate or resistant were found susceptible on central re-testing.
* Corresponding author. Tel: +44-20-8200-4400 ext. 4282; Fax: +44-20-8358-3292; E-mail: chenwood{at}phls.org.uk
Members of the Pseudomonas Study Group are listed in the Acknowledgements.
Deceased. This paper is dedicated to his memory.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. B. Bulitta, S. B. Duffull, M. Kinzig-Schippers, U. Holzgrabe, U. Stephan, G. L. Drusano, and F. Sorgel Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2497 - 2507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Macia, N. Borrell, M. Segura, C. Gomez, J. L. Perez, and A. Oliver Efficacy and Potential for Resistance Selection of Antipseudomonal Treatments in a Mouse Model of Lung Infection by Hypermutable Pseudomonas aeruginosa Antimicrob. Agents Chemother., March 1, 2006; 50(3): 975 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Macia, D. Blanquer, B. Togores, J. Sauleda, J. L. Perez, and A. Oliver Hypermutation Is a Key Factor in Development of Multiple-Antimicrobial Resistance in Pseudomonas aeruginosa Strains Causing Chronic Lung Infections Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3382 - 3386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Poole Aminoglycoside Resistance in Pseudomonas aeruginosa Antimicrob. Agents Chemother., February 1, 2005; 49(2): 479 - 487. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Morrissey, M. Robbins, L. Viljoen, and D. F. J. Brown Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods J. Antimicrob. Chemother., February 1, 2005; 55(2): 200 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Macia, N. Borrell, J. L. Perez, and A. Oliver Detection and Susceptibility Testing of Hypermutable Pseudomonas aeruginosa Strains with the Etest and Disk Diffusion Antimicrob. Agents Chemother., July 1, 2004; 48(7): 2665 - 2672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. C. Potz, S. Mushtaq, A. P. Johnson, C. J. Henwood, R. A. Walker, E. Varey, M. Warner, D. James, and D. M. Livermore Reliability of routine disc susceptibility testing by the British Society for Antimicrobial Chemotherapy (BSAC) method J. Antimicrob. Chemother., May 1, 2004; 53(5): 729 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T L Pitt, M Sparrow, M Warner, and M Stefanidou Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents Thorax, September 1, 2003; 58(9): 794 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Steward, J. M. Mohammed, J. M. Swenson, S. A. Stocker, P. P. Williams, R. P. Gaynes, J. E. McGowan Jr., and F. C. Tenover Antimicrobial Susceptibility Testing of Carbapenems: Multicenter Validity Testing and Accuracy Levels of Five Antimicrobial Test Methods for Detecting Resistance in Enterobacteriaceae and Pseudomonas aeruginosa Isolates J. Clin. Microbiol., January 1, 2003; 41(1): 351 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T L Pitt Cross infection of cystic fibrosis patients with Pseudomonas aeruginosa Thorax, November 1, 2002; 57(11): 921 - 921. [Full Text] [PDF]
|
|
|
|
 |
|
 P T Heath and A S Breathnach Treatment of infections due to resistant organisms: Childhood respiratory infections Br. Med. Bull., March 1, 2002; 61(1): 231 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Landrygan, P. A. James, D. Brooks, and E. M. Kubiak Reproducibility of control organism zone diameters for batches of IsoSensitest agar manufactured from 1996 to 2000 using the BSAC disc susceptibility test method J. Antimicrob. Chemother., February 1, 2002; 49(2): 391 - 394. [Abstract] [Full Text] [PDF]
|
|